FendX Technologies Inc Stock Price, News & Analysis

FendX (OTCQB: FDXTF, CSE: FNDX, FSE: E8D0) announced extensions of two consulting agreements for branding and strategic marketing support. One agreement with a branding expert was extended to May 10, 2026 on the same monthly fee terms; the second consultant agreement was extended to June 15, 2026 on the same monthly fee terms. The company said it may renew either agreement for additional one‑month or multi‑month periods at its discretion.

The update discloses no changes to fees or material financial terms beyond the identical monthly fee arrangements and provides timeline clarity for near‑term consultant support through mid‑2026.

FendX (OTCQB: FDXTF) signed a Memorandum of Understanding dated November 17, 2025 with Aquaox to pursue development of advanced formulations of eco‑friendly pathogen‑eliminating agents for use in cleaning and disinfectant products across healthcare, consumer, and commercial markets.

The MOU contemplates a collaboration and supply relationship under a future Definitive Agreement, states Aquaox will oversee production equipment and supply, and says FendX will own any products and new intellectual property while Aquaox will own any new EPA certifications. The MOU term is 12 months and the Definitive Agreement is subject to due diligence and regulatory and corporate approvals, with no assurance it will be completed.

FendX (OTCQB: FDXTF) filed a provisional patent application with the US Patent and Trademark Office for an "Antimicrobial Coating for Long-Lasting Pathogen Control on High-Touch Surfaces" (application no. 63/936,328), filed August 7, 2025, with FendX as assignee.

The application, prepared by Drs. Carolyn Myers, Tohid Didar, Leyla Soleymani and Sara Moetakef Imani, describes a novel nanoparticle liquid coating engineered for easy application (roller or brush) to actively disrupt microbial contamination and provide sustained protection on high-touch surfaces. The company said it is assessing scale-up and distribution partnership opportunities to commercialize the technology.

FendX Technologies (OTCQB: FDXTF) announced that CEO Dr. Carolyn Myers has filed a provisional patent application for an AI-powered pathogen detection platform. The patent, titled "AI Adaptive App Pathogen Detection Platform," was filed on June 25, 2025, with the United States Patent and Trademark Office.

The technology combines mobile-based imaging, biosensor technology, and artificial intelligence to enable real-time pathogen detection on surfaces using smartphones. The innovation aims to create a portable diagnostic tool for both consumer and professional applications, moving beyond traditional lab-based testing methods.

FendX Technologies (OTCQB: FDXTF), a surface protection technology company, has announced a 10-for-1 share consolidation effective August 18, 2025. The consolidation will reduce the company's outstanding shares from 90,019,646 to approximately 9,001,965 shares.

The company's board approved this consolidation to optimize its share structure, potentially attract additional financing, and position FendX for growth. The stock will continue trading under the symbol "FNDX" with new CUSIP and ISIN numbers. Endeavor Trust Corporation will handle the administrative process of exchanging pre-consolidation shares for post-consolidation certificates.

FendX Technologies has engaged a branding expert through a consulting agreement dated June 10, 2025, to support the branding and marketing of its upcoming eco-friendly sponge product line. The consultant will help develop brand identity, including naming, visual elements, and marketing materials for global consumer, retail, and commercial cleaning markets. The six-month agreement includes a monthly consulting fee of $5,000 paid quarterly in company shares, plus 250,000 stock options. The agreement runs until December 9, 2025, with an option for renewal and includes a 7-day termination notice provision. This follows FendX's April 24 announcement of an exclusive supply agreement for proprietary foam manufacturing.

FendX Technologies (FDXTF) has completed a share issuance of 1,000,000 common shares at $0.10 per share to Scott Smith as part of an exclusive intellectual property license agreement. The agreement grants FendX exclusive rights to three patent applications related to BioFoam® technology, which involves using Open-Cell foam for surface cleaning and potential wound care drug delivery applications.

Additionally, FendX secured a supply agreement with US BioSolutions to receive bulk rolls of Open-Cell foam, manufactured using proprietary methods. This agreement enables FendX to develop and distribute eco-friendly sponge products across consumer, retail, and commercial cleaning markets. The issued shares are subject to hold periods in both Canada and the United States.

FendX Technologies (FDXTF) has entered into two significant agreements on April 23, 2025: an exclusive supply agreement with US BioSolutions for Open-Cell foam, and an IP license agreement including three pending patents and the BioFoam® trademark. The agreements enable FendX to develop eco-friendly sponge products for global cleaning markets.

The sponge products will offer sustainable alternatives to traditional sponges, being washable, reusable, biodegradable, and resistant to bacterial growth without toxic plasticizers. The North American household cleaner sponge market is valued at US$1.96 billion in 2024 and projected to reach US$2.92 billion by 2033.

As consideration for the IP license, FendX will issue 1,000,000 common shares at $0.10 per share to Scott Smith, CEO of US BioSolutions. The supply agreement includes a predetermined price per square foot for the first 12 months, with provisions for future price and volume negotiations.

FendX Technologies (FDXTF) highlights recent CDC reports on the growing threat of antimicrobial resistance (AR). The CDC report from February 4, 2025, reveals that over 2.8 million antimicrobial-resistant infections occur annually in the U.S., causing at least 1.27 million deaths worldwide. The estimated cost to treat six common AR infections in healthcare settings exceeds US$4.6 billion annually.

The report notably identifies a concerning 5-fold increase in Candida auris cases from 2019 to 2022, with recent surges reported in New York, Georgia, and Florida. The CDC has classified this drug-resistant yeast as an 'urgent threat.'

In response, FendX is developing surface protection products, including their REPELWRAP™ film currently undergoing real-world testing. The company recently signed a letter of intent with US BioSolutions for acquiring IP and establishing a supply agreement for an eco-friendly microbe-trapping sponge.